Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Receives Average Rating of “Buy” from Brokerages

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have received an average rating of “Buy” from the five brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $15.3333.

A number of equities analysts have weighed in on RADX shares. B. Riley restated a “buy” rating and issued a $16.00 price target (up previously from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Radiopharm Theranostics to a “strong sell” rating in a research note on Friday, January 23rd.

Radiopharm Theranostics Stock Up 2.2%

Shares of NASDAQ RADX opened at $5.03 on Friday. Radiopharm Theranostics has a 1-year low of $3.50 and a 1-year high of $16.25. The business has a 50-day moving average of $5.05 and a 200-day moving average of $5.35.

Institutional Investors Weigh In On Radiopharm Theranostics

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. boosted its holdings in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,000 shares of the company’s stock after purchasing an additional 8,000 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent quarter.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.